STAAR Surgical (NASDAQ:STAA) Given New $20.00 Price Target at Stifel Nicolaus

STAAR Surgical (NASDAQ:STAA) had its target price reduced by Stifel Nicolaus from $38.00 to $20.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

Several other research firms have also weighed in on STAA. Stephens raised STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research note on Wednesday. BTIG Research cut shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday. Canaccord Genuity Group cut their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Finally, Mizuho lowered shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $45.00 to $17.00 in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.43.

STAAR Surgical Stock Down 24.7 %

STAA stock opened at $16.48 on Wednesday. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68. The company has a market cap of $812.13 million, a P/E ratio of 37.45 and a beta of 0.62. The business’s fifty day moving average is $23.75 and its 200-day moving average is $29.24.

Insider Transactions at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock in a transaction dated Thursday, January 16th. The stock was bought at an average cost of $21.50 per share, with a total value of $176,751.50. Following the completion of the transaction, the insider now directly owns 10,878,007 shares of the company’s stock, valued at approximately $233,877,150.50. This represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders purchased 105,876 shares of company stock valued at $2,487,168 over the last quarter. Corporate insiders own 1.00% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

A number of hedge funds and other institutional investors have recently bought and sold shares of STAA. Vanguard Group Inc. grew its stake in shares of STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after acquiring an additional 319,441 shares in the last quarter. Yunqi Capital Ltd boosted its holdings in STAAR Surgical by 48.9% during the fourth quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock worth $18,640,000 after purchasing an additional 252,113 shares during the last quarter. JPMorgan Chase & Co. grew its position in STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after purchasing an additional 172,779 shares in the last quarter. American Capital Management Inc. increased its stake in STAAR Surgical by 42.9% in the 3rd quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier’s stock valued at $19,051,000 after buying an additional 154,037 shares during the last quarter. Finally, Jupiter Asset Management Ltd. lifted its position in STAAR Surgical by 36.7% during the 4th quarter. Jupiter Asset Management Ltd. now owns 377,249 shares of the medical instruments supplier’s stock worth $9,163,000 after buying an additional 101,373 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.